

To: [REDACTED] [REDACTED] [REDACTED]@rivm.nl; [REDACTED] [REDACTED] [REDACTED]@rivm.nl; [REDACTED]
[REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED] [REDACTED]
Sent: Sat 2/20/2021 12:01:41 PM
Subject: Commercial MTA for EVAg
Received: Sat 2/20/2021 12:01:42 PM
[Comparison EVAg MTA with commercial EVAg MTA.docx](#)
[commercial MTA EVAg template.docx](#)

Dear all,

I received a template for an EVAg MTA with commercial entities. I compared it with the standard MTA that we use for TNA orders (file is attached). There are only a few differences. For previous commercial orders we included the statements below in the MTA:

1. In the perspective of the utmost importance of research on pharmaceutical products as countermeasures for the ongoing COVID-19 pandemic, RIVM is willing to provide these materials on a one time basis.
2. The materials can be used for scientific research and validation, but (parts of) the materials (nor derivates) cannot be integrated into the final products that will be put on the market.

I therefore propose to contact the commercial entities that have ordered with us and propose the commercial MTA template from EVAg, including the 2 points above.

If there are any questions or suggestions how to proceed differently, please let me know. Otherwise, we will proceed like this.

Thank you for your help.

Best wishes,

[REDACTED]

Contact:
Werkplek [REDACTED]
T: [REDACTED]
M: [REDACTED]
e-mail: [REDACTED]@rivm.nl